Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Popplewell

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 18, 2022
Systemic Delivery of a Monoclonal Antibody to Immunologically Block Myostatin in the A17 Mouse Model of OPMDAlberto Malerba, Pradeep Harish, Linda Popplewell
Muscles (Basel, Switzerland)|November 24, 2025
Dystrophin Restorative and Compensatory Gene Addition Therapies for Duchenne Muscular Dystrophy: Could CRISPRa Provide a Realistic Alternative?Zakaria Rostamitehrani, Rida Javed, Linda Popplewell
Human Gene Therapy|June 1, 2012
Genetic therapeutic approaches for Duchenne muscular dystrophyHelen Foster, Linda Popplewell, George Dickson
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2022
Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense TreatmentNgoc Lu-Nguyen, Alberto Malerba, Linda Popplewell
Human Gene Therapy|November 7, 2013
Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic miceTaeyoung Koo, Linda Popplewell, Takis Athanasopoulos, et al.
Expert Opinion on Biological Therapy|December 7, 2013
New developments in the use of gene therapy to treat Duchenne muscular dystrophySusan Jarmin, Hanna Kymalainen, Linda Popplewell, et al.
Biomedicines|July 27, 2022
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit <i>DUX4</i> ExpressionNgoc Lu-Nguyen, George Dickson, Alberto Malerba, et al.
International Journal of Molecular Sciences|July 13, 2024
Systemic Pharmacotherapeutic Treatment of the ACTA1-MCM/FLExDUX4 Preclinical Mouse Model of FSHDNgoc Lu-Nguyen, Stuart Snowden, Linda Popplewell, et al.
International Journal of Molecular Sciences|June 19, 2024
Targeted Antisense Oligonucleotide-Mediated Skipping of Murine <i>Postn</i> Exon 17 Partially Addresses Fibrosis in D2.<i>mdx</i> MiceJessica Trundle, Ngoc Lu-Nguyen, Alberto Malerba, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2018
Antisense Oligonucleotide Targeting of 3'-UTR of mRNA for Expression KnockdownGolnoush Golshirazi, Lukasz Ciszewski, Ngoc Lu-Nguyen, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Methods in Molecular Biology (Clifton, N.J.)|November 18, 2022
Systemic Delivery of a Monoclonal Antibody to Immunologically Block Myostatin in the A17 Mouse Model of OPMDAlberto Malerba, Pradeep Harish, Linda Popplewell
Muscles (Basel, Switzerland)|November 24, 2025
Dystrophin Restorative and Compensatory Gene Addition Therapies for Duchenne Muscular Dystrophy: Could CRISPRa Provide a Realistic Alternative?Zakaria Rostamitehrani, Rida Javed, Linda Popplewell
Human Gene Therapy|June 1, 2012
Genetic therapeutic approaches for Duchenne muscular dystrophyHelen Foster, Linda Popplewell, George Dickson
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2022
Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense TreatmentNgoc Lu-Nguyen, Alberto Malerba, Linda Popplewell
Human Gene Therapy|November 7, 2013
Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic miceTaeyoung Koo, Linda Popplewell, Takis Athanasopoulos, et al.
Expert Opinion on Biological Therapy|December 7, 2013
New developments in the use of gene therapy to treat Duchenne muscular dystrophySusan Jarmin, Hanna Kymalainen, Linda Popplewell, et al.
Biomedicines|July 27, 2022
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit <i>DUX4</i> ExpressionNgoc Lu-Nguyen, George Dickson, Alberto Malerba, et al.
International Journal of Molecular Sciences|July 13, 2024
Systemic Pharmacotherapeutic Treatment of the ACTA1-MCM/FLExDUX4 Preclinical Mouse Model of FSHDNgoc Lu-Nguyen, Stuart Snowden, Linda Popplewell, et al.
International Journal of Molecular Sciences|June 19, 2024
Targeted Antisense Oligonucleotide-Mediated Skipping of Murine <i>Postn</i> Exon 17 Partially Addresses Fibrosis in D2.<i>mdx</i> MiceJessica Trundle, Ngoc Lu-Nguyen, Alberto Malerba, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2018
Antisense Oligonucleotide Targeting of 3'-UTR of mRNA for Expression KnockdownGolnoush Golshirazi, Lukasz Ciszewski, Ngoc Lu-Nguyen, et al.
Pageof 5